Rubius Therapeutics Reports Net Loss of $179.7 Million for 2022
Revenue remains unchanged as Rubius Therapeutics releases its financial results for the year
Rubius Therapeutics, Inc.(RUBY) announced its consolidated financial results for the year ended December 31, 2022, revealing a net loss of $179.7 million and no revenue. The company's balance sheet showed total assets of $23.1 million, with current assets amounting to $20.2 million. The financial report highlights Rubius Therapeutics' operating expenses, including research and development costs of $96.4 million and general and administrative expenses of $30.8 million.**
Net Loss of $179.7 Million for 2022
Rubius Therapeutics, Inc., a biopharmaceutical company focused on the development of innovative cellular therapies, reported a net loss of $179.7 million for the year ended December 31, 2022. This loss reflects the company's ongoing investment in research and development, as well as general operating expenses.
